Sensus Healthcare, Inc. (SRTS) Trades at $5.56 After Triangle; Last Week Intec Pharma Ltd. (NTEC) Analysts

Sensus Healthcare, Inc. (SRTS) formed triangle with $5.12 target or 8.00% below today’s $5.56 share price. Sensus Healthcare, Inc. (SRTS) has $75.29M valuation. The stock decreased 1.40% or $0.0789 during the last trading session, reaching $5.5611. About 1,648 shares traded. Sensus Healthcare, Inc. (NASDAQ:SRTS) has 0.00% since February 28, 2017 and is . It has underperformed by 16.70% the S&P500.

Among 4 analysts covering Intec Pharma (NASDAQ:NTEC), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Intec Pharma had 9 analyst reports since September 11, 2015 according to SRatingsIntel. The firm has “Buy” rating by Roth Capital given on Monday, July 24. Oppenheimer maintained Intec Pharma Ltd. (NASDAQ:NTEC) on Thursday, November 16 with “Buy” rating. On Friday, September 11 the stock rating was initiated by Roth Capital with “Buy”. The rating was initiated by TH Capital with “Buy” on Friday, September 11. Roth Capital maintained Intec Pharma Ltd. (NASDAQ:NTEC) on Thursday, August 3 with “Buy” rating. Roth Capital maintained it with “Buy” rating and $9.5000 target in Thursday, August 10 report. The rating was maintained by Oppenheimer on Thursday, September 21 with “Buy”. The stock of Intec Pharma Ltd. (NASDAQ:NTEC) has “Buy” rating given on Wednesday, September 16 by Maxim Group. Oppenheimer initiated it with “Buy” rating and $1000 target in Thursday, June 22 report. See Intec Pharma Ltd. (NASDAQ:NTEC) latest ratings:

16/11/2017 Broker: Oppenheimer Rating: Buy New Target: $15.0 Maintain
21/09/2017 Broker: Oppenheimer Rating: Buy New Target: $15.0 Maintain

Analysts await Sensus Healthcare, Inc. (NASDAQ:SRTS) to report earnings on May, 3. They expect $-0.03 earnings per share, up 75.00% or $0.09 from last year’s $-0.12 per share. After $-0.03 actual earnings per share reported by Sensus Healthcare, Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

The stock increased 2.61% or $0.15 during the last trading session, reaching $5.9. About 133,056 shares traded or 5.64% up from the average. Intec Pharma Ltd. (NASDAQ:NTEC) has risen 51.00% since February 28, 2017 and is uptrending. It has outperformed by 34.30% the S&P500.

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. The company has market cap of $160.71 million. The Company’s Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. It currently has negative earnings. The companyÂ’s lead product candidate is Accordion Pill Carbidopa/Levodopa , which is in a Phase III clinical trial for the treatment of ParkinsonÂ’s disease symptoms in advanced ParkinsonÂ’s disease patients.